Ghussen F, Nagel K, Groth W, Horbach G
Z Hautkr. 1985 Oct 15;60(20):1613-9.
The concentrations of indole melanogens have been measured in 24-hour urine samples of 44 patients suffering from malignant melanoma, clinical stages I to IV, and 23 healthy test persons (control group). With regard to the controls, the urinary concentration of indole melanogens amounted to 3.8 +/- 1.329 micrograms/ml; the excretion was 5.41 +/- 1.941 mg daily. In patients with localized malignant melanoma, the concentration of indole melanogens did not differ from the control group. Highly significant levels, however, were measured in patients with generalized disease (7.76 micrograms/ml and 6.85 mg daily). Tyrosin orally given (7 g on the 2nd, 3rd, and 4th day of the collecting period) did not elevate the urinary excretion of indole melanogens in any of the test groups. These results indicate that the applied procedure does not present any fundamental advantage for clinical oncology.
已对44例患有I至IV期恶性黑色素瘤的患者以及23名健康测试者（对照组）的24小时尿液样本中的吲哚黑素原浓度进行了测量。对于对照组，吲哚黑素原的尿液浓度为3.8±1.329微克/毫升；每日排泄量为5.41±1.941毫克。局限性恶性黑色素瘤患者的吲哚黑素原浓度与对照组无差异。然而，在患有全身性疾病的患者中测得的水平非常显著（7.76微克/毫升和每日6.85毫克）。在收集期的第2、3和4天口服酪氨酸（7克）并未使任何测试组中的吲哚黑素原尿液排泄量增加。这些结果表明，所应用的方法对临床肿瘤学没有任何根本优势。
